ClinicalTrials.gg
TerminatedNCT04578106ELPISUpdated Jan 6, 2026Results posted

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

A Phase 2 interventional study of Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination in HER2-positive Breast Cancer and Stage I Breast Cancer, sponsored by Fundacio Clinic Barcelona. Terminated at 1 site in Spain. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Fundacio Clinic Barcelona · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
342nd of 366
5 · median 61
Started
2020
with 12 others
Phase 2
239 of 374
44 open now
Registered
288th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 342nd largest by enrollment of the 366 interventional ones that give a count, is one of 13 that started in 2020, is one of 239 in phase 2, and was the 288th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic subtype and a ERBB2 pre-defined cutoff (high vs low ERBB2 expression), to evaluate the omission of surgery and sentinel lymph node dissection in patients with HER2-E and ERBB2 high breast cancer who achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab. The primary trial objective is to estimate the loco-regional invasive disease-free survival at 3-year of patients who achieve a complete response based on imaging (i.e. Magnetic resonance imaging) and a stereotactic-guided vacuum-assisted breast biopsy, and omit loco-regional surgery.

03

Conditions studied

  • HER2-positive Breast Cancer
  • Stage I Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Her2-positive
  • Pertuzumab
  • Trastuzumab
  • Omission surgery
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants who are at least 40 years of age on the day of signing the form with confirmed diagnosis of breast cancer.
  2. A participant is eligible to participate if she is not pregnant, not breastfeeding.
  3. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  4. Histologically confirmed invasive adenocarcinoma of the breast, with all of the following characteristics:

    • -positive status by local determination according to 2018 ASCO/CAP guidelines.
    • PAM50 HER2-enriched subtype and ERBB2-high as predefined cutoff as per central determination.
    • Unifocal invasive carcinoma: only 1 invasive focus can be observed (the tumor focus containing or not containing an in situ component)
    • Tumor largest diameter ≤4 cm as defined by breast MRI.
    • No nodal involvement (i.e. cN0). Any suspicious axillary node by ultrasound must be biopsied. If the or the FNA is negative of tumor cells, patient is eligible.
    • No evidence of distant (M0) by routine clinical assessment.
  5. Patient must have known ER and PR status locally determined prior to study entry.
  6. Eligible for taxane therapy.
  7. Willingness of the patient to omit surgery if all criteria are met following therapy.
  8. Estimated of at least 5 years irrespective of the diagnosis of breast cancer.
  9. Breast cancer eligible for primary surgery
  10. Have provided archival tumor tissue sample or newly obtained core. Formalin-fixed,paraffin embedded (FFPE) tissue blocks are mandatory. Available pre-treatment FFPE core biopsy evaluable for PAM50 or possibility to obtain one.
  11. Have an (ECOG) performance status of 0 to 1.
  12. Ability and willingness to comply with study visits, treatment, testing and to comply with the protocol.
  13. Have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Has received prior anti-cancer therapy, including agents, or treatment for primary invasive breast cancer.
  2. Known to any of the of trastuzumab, pertuzumab, TDM1 or paclitaxel.
  3. Clinical stage II, III or IV.
  4. History of radiotherapy in the ipsilateral breast or axilla.
  5. History of surgery of the ipsilateral axilla.
  6. Bilateral invasive breast cancer.
  7. Infiltrating lobular carcinoma.
  8. Multicentric or multifocal breast cancer, defined as the presence of two or more foci of cancer in the same or different quadrants of the same breast.
  9. Patients who have undergone sentinel lymph node prior to study treatment.
  10. Patient has active cardiac disease or a history of cardiac dysfunction
  11. Has an active infection requiring systemic therapy.

13. Patients with a history of previous breast cancer are excluded.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Omission of surgery

    Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Adjuvant period: If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB,patients will be eligible to omit loco-regional surgery. Whole breast radiotherapy without nodal radiotherapy will then be performed. Trastuzumab and pertuzumab FDC will be continued to complete 1 year of treatment and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.

    Biological: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination

  • No intervention
    Surgery

    Neoadjuvant period: paclitaxel IV 80mg/m2 every week for 12 weeks with trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination (FDC) (a loading dose of 1200 mg pertuzumab and 600 mg trastuzumab followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks) for 5 cycles. Surgery: If invasive tumor cells and/or in situ disease are identified, patients will undergo surgery. Adjuvant period: All patients will continue with Trastuzumab-emtansine (T-DM1) completing 1 year of treatment (14 cycles) and adjuvant endocrine therapy will be indicated according to hormonal receptor status by IHC.

Interventions

  • BiologicalTrastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination

    Drug pages: TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.

    Also known as: Omission of surgery

This study also gives Ado-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Disease-free Survival at 3years

    To estimate the loco-regional invasive disease-free survival (LR-IDFS) at 3-year of patients who achieve a complete response based on imaging and a stereotactic-guided vacuum-assisted breast biopsy, and omit loco-regional surgery.

    Time frame: 3 years

Secondary outcomes

  1. pCR Rate

    rate of pathological complete response (pCR) between the treatment groups by HR status

    Time frame: pCR assessment was done following surgery after neoadjuvant therapy with paclitaxel and trastuzumzb/pertuzumab prior to adjuvant therapy

  2. Patient Reported Outcomes (Global Health Status)

    The EORTC QLQ-C30 was used to assess Health-Related Quality of Life (QoL). The measure consists of five functional scales (physical, role, cognitive, emotional, and social). For this study, raw scores were used without any transformation. The functional scales consist of multiple items (questions 1-28) scored on a 1-4 scale (1 = not at all, 4 = very much). Higher scores indicate worse functioning. To assess the effect of standard therapy (surgery after neoadjuvant therapy) vs. investigational therapy (omission of surgery), the global health status is reported in each of these populations before and after treatment. The Global Health Status (GHS) score is derived from two items (Q29 and Q30), each scored on a 1-7 scale (1 = very poor, 7 = excellent). Scoring method: GHS = (Q29 + Q30) / 2 Raw score range: Minimum = (1 + 1) / 2 = 1; Maximum = (7 + 7) /2 = 7

    Time frame: The questionnaire was filled by the patients at screening and post adjuvant therapy.

07

Results

Posted Jan 6, 2026

Participant flow

Overall, 20 patients were screened for the study in a single study centre (clinical setting) over the duration of 18 months. A total of 5 patients were finally selected for the study treatment after meeting all the inclusion criteria and signing the ICF

Study treatment
Participant flow — Study treatment
MilestoneTreatment Arm
Started5
Completed5
Not completed0
Follow-up after 1 year
Participant flow — Follow-up after 1 year
MilestoneTreatment Arm
Started5
Completed4
Not completed1
Withdrew: Lost to follow-up1
Follow up at 3 yrs
Participant flow — Follow up at 3 yrs
MilestoneTreatment Arm
Started4
Completed0
Not completed4

Outcome measures

PrimaryDisease-free Survival at 3years

To estimate the loco-regional invasive disease-free survival (LR-IDFS) at 3-year of patients who achieve a complete response based on imaging and a stereotactic-guided vacuum-assisted breast biopsy, and omit loco-regional surgery.

Time frame:
3 years
Reported as:
Median · years

No measurements were reported for this outcome.

SecondarypCR Rate

rate of pathological complete response (pCR) between the treatment groups by HR status

Time frame:
pCR assessment was done following surgery after neoadjuvant therapy with paclitaxel and trastuzumzb/pertuzumab prior to adjuvant therapy
Reported as:
Count of participants · Participants
pCR Rate
ParticipantsHR PositiveHR Negative
pCR Rate02
SecondaryPatient Reported Outcomes (Global Health Status)

The EORTC QLQ-C30 was used to assess Health-Related Quality of Life (QoL). The measure consists of five functional scales (physical, role, cognitive, emotional, and social). For this study, raw scores were used without any transformation. The functional scales consist of multiple items (questions 1-28) scored on a 1-4 scale (1 = not at all, 4 = very much). Higher scores indicate worse functioning. To assess the effect of standard therapy (surgery after neoadjuvant therapy) vs. investigational therapy (omission of surgery), the global health status is reported in each of these populations before and after treatment. The Global Health Status (GHS) score is derived from two items (Q29 and Q30), each scored on a 1-7 scale (1 = very poor, 7 = excellent). Scoring method: GHS = (Q29 + Q30) / 2 Raw score range: Minimum = (1 + 1) / 2 = 1; Maximum = (7 + 7) /2 = 7

Time frame:
The questionnaire was filled by the patients at screening and post adjuvant therapy.
Reported as:
Median · score on a scale
Patient Reported Outcomes (Global Health Status)
score on a scalePatients Who Underwent Surgery (Assessment at Screening)Patients Who Underwent Surgery (Assessment After Adjuvant Therapy)Patients With Omission of Surgery (Assessment at Screening)Patients With Omission of Surgery (Assessment After Adjuvant Therapy)
Patient Reported Outcomes (Global Health Status)5 (5 to 6)4 (3.5 to 4.5)5.25 (4.5 to 6)5 (4 to 6)

Adverse events

Collected over Study treatment duration - 1 year (neoadjuvant and adjuvant therapy). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm (Treatment With Paclitaxel)0/5 (0%)0/5 (0%)5/5 (100%)
Treatment Arm (Treatment With Trastuzumab)0/5 (0%)0/5 (0%)5/5 (100%)
Treatment Arm (Treatment With Pertuzumab)0/5 (0%)0/5 (0%)5/5 (100%)
Treatment Arm (Adjuvant Treatment With TDM1)0/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventTreatment Arm (Treatment With Paclitaxel)Treatment Arm (Treatment With Trastuzumab)Treatment Arm (Treatment With Pertuzumab)Treatment Arm (Adjuvant Treatment With TDM1)
alat increaseHepatobiliary disorders0/50/50/53/3
alopeciaSkin and subcutaneous tissue disorders4/50/50/50/3
diarrheaGastrointestinal disorders1/54/54/50/3
asat increaseHepatobiliary disorders0/50/50/52/3
epigastralgiaGastrointestinal disorders0/50/50/52/3
increase of alkaline phosphataseHepatobiliary disorders0/50/50/52/3
erythema arms and handsSkin and subcutaneous tissue disorders3/50/50/50/3
astheniaGeneral disorders2/51/51/51/3
dysguesiaMetabolism and nutrition disorders2/51/51/50/3
headacheNervous system disorders2/50/50/50/3

Baseline characteristics

The baseline analysis population is the same as the treatment population

Age, Customized
Age, Customized(participants)Treatment Arm
>= 40 yrs5
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm
Female5
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Treatment Arm
Caucasian5
Region of Enrollment
Region of Enrollment(participants)Treatment Arm
Spain5
Menopausal Status
Menopausal Status(participants)Treatment Arm
Postmenopausal (min 12 mnths without menses before neoadyuvance treatment)4
premenopausal1
ECOG baseline
ECOG baseline(participants)Treatment Arm
Grade 04
Grade 11
Previous cancer history
Previous cancer history(participants)Treatment Arm
Yes0
No5
08

Study locations

1 site
  • Hospital Clinic de Barcelona
    Barcelona, Barcelona 08036, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jul 2024, 45 months.

Results were first posted in Jan 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 8, 2020
StartActual
Sep 23, 2020
Primary completionActual
Jul 16, 2024
CompletionActual
Jul 16, 2024
Results first posted
Jan 6, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04578106
Lead sponsor
Fundacio Clinic Barcelona
Collaborators
SOLTI Breast Cancer Research Group, Roche Pharma AG
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Sep 23, 2020
Primary completion
Jul 16, 2024
Completion
Jul 16, 2024
Results posted
Jan 6, 2026
Last update
Jan 6, 2026

Study contacts

Aleix Prat, MD
principal investigator · Hospital Clinic of Barcelona
Tomas Pascual, MD
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Pertuzumab

Start the discussion